Capmatinib
Tabrecta, Capmatinib (capmatinib) is a small molecule pharmaceutical. Capmatinib was first approved as Tabrecta on 2008-06-10. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor. Tabrecta’s patents are valid until 2035-07-22 (FDA).
Trade Name |
Capmatinib |
---|---|
Common Name |
capmatinib |
ChEMBL ID |
CHEMBL3188267 |
Indication |
breast neoplasms, non-small-cell lung carcinoma |
Drug Class |
Tyrosine kinase inhibitors |
Image (chem structure or protein)
$4,995
Want to know more?
Schedule a demo or contact us for additional purchasing options.
Every Drug Dataset Includes...
Full dataset compatible with-

SQL for web applications

R for statistical modeling

Spotfire & Tableau for visualization

CSV export file format

JSON export file format

XLSX export file format
Continually updated information available as a yearly subscription for individual drug-of-interest.